Kymera Therapeutics to Present New Preclinical Data of IRAK4 Degraders in MYD88-Mutant Lymphoma at American Association for Cancer Research Annual Meeting
Cambridge, Mass. (March 1, 2019) -- Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, today announced the company will present new preclinical data for its first-in-class oral IRAK4 protein degrader, KYM-001, at a late-breaker session at the Annual Meeting of the American Association for Cancer Research (AACR), March 29-April 3, 2019 in Atlanta, Georgia.
"KYM-001, a first-in-class oral IRAK4 protein degrader, induces tumor regression in xenograft models of MYD88-mutant ABC DLBCL alone and in combination with BTK inhibition" will be presented by Joseph Kelleher, PhD, Senior Director and Head of Discovery Biology, and Nello Mainolfi, PhD, Founder and Chief Scientific Officer. Additional Kymera executives present at AACR and the poster session will include Jared Gollob, MD, Chief Medical Officer and Mark Nuttall, PhD, Chief Business Officer.
Poster #18, Late-Breaking Research: Experimental and Molecular Therapeutics 2 Session
Presentation Date: Wednesday, April 3, 8:00 AM - 12:00 PM
Session Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 40
About Kymera Therapeutics
Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus(TM), a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. For more information visit, www.kymeratx.com.
CONTACT: Lissette Steele, 202-431-4116, lsteele@vergescientific.com
/PRNewswire -- March 1, 2019/
SOURCE Kymera Therapeutics Inc.
